Track 04 · the dose record
BPC-157 TB-500 Dosage Reported in Preclinical Studies
Component-level animal-study doses, routes, and half-lives — and why no validated blend dose exists. Research context, not a human protocol.
BPC-157 and TB-500 Dosage Ranges Reported in Preclinical Studies
There is no validated dose for the BPC-157 TB-500 blend. Commercial research-product labeling commonly pairs the two at fixed combined masses per vial (for example ~10 mg BPC-157 + ~10 mg TB-500, or a 20 mg combined vial), but no peer-reviewed combination dose-finding study exists [6]. Every figure below is a dose administered to animals in a specific study, reported as such — not guidance for human use.
For the BPC-157 component, rodent studies commonly express dose per body weight, frequently around 10 μg/kg and 10 ng/kg; the transected-Achilles result used those ranges intraperitoneally [1], and gastric-ulcer cytoprotection has been studied at 400-800 ng/kg in rats. For the TB-500 / Thymosin Beta-4 component, the range is wide: a rat embolic-stroke dose-response study spanned 2-18 mg/kg intraperitoneally, with an optimal modeled around 3.75 mg/kg and 18 mg/kg giving no benefit — higher was not better [4]. An mdx muscular-dystrophy study used 150 μg twice weekly intraperitoneally for six months [4].
The honest summary: the constituents have animal-model dose records; the blend does not. Anyone presenting a fixed-ratio vial as a validated dose is presenting community practice, not controlled-trial evidence [6].
What is the half-life of BPC-157 and TB-500?
No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study. Human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses, but no specific half-life is established for the TB-500 heptapeptide [4].
What is the half-life of BPC-157 and TB-500?
No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study. Human IV full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide [4]. See half-life and reconstitution below.
How do you cycle BPC-157 and TB-500?
No validated human cycling protocol appears in the literature. Community "loading then maintenance" blend schedules have no controlled-trial basis, and a rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic — 18 mg/kg gave no benefit — which undercuts "more is better" loading rationales [4]. The underlying animal studies use widely differing schedules by species and route.
How often should you inject BPC-157 and TB-500?
The literature records no validated human injection frequency for the blend. The underlying animal studies use widely differing schedules — for example Thymosin Beta-4 at 150 μg twice weekly intraperitoneally for six months in one mouse study [4] — and community frequency protocols have no controlled-trial basis. Findings should be described as "studied at X in [species]," not framed as human schedules.
Routes of Administration Reported in the Component Literature
The wolverine injection question — how the blend is administered — has only a research-context answer. In the underlying rodent efficacy studies for both peptides, the predominant route was intraperitoneal [1][4]. Subcutaneous and intramuscular routes predominate in research-community practice but not in controlled human efficacy trials. Intravenous administration appears in human Phase 1 work on full-length Thymosin Beta-4 and a BPC-157 safety pilot. Local, intra-lesional, and topical routes appear in individual-compound wound and tendon models.
None of these is a human-use instruction. They describe how the molecules were delivered in the studies that generated the findings.
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. Commercial vials are commonly labeled with a combined per-vial mass (e.g. 10 mg + 10 mg), but product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. No human-use reconstitution instructions apply to a research chemical.
Oral vs. Parenteral Administration in Reviewed Preclinical Models
The "bpc 157 tb 500 oral" question turns on a real difference between the two peptides. BPC-157 is studied in the literature as a "stable gastric" peptide, with peroral administration appearing in some rodent models. TB-500 / Thymosin Beta-4 work is overwhelmingly parenteral. Either way, no validated oral pharmacokinetics exist for the blend, and oral blend products that are marketed lack a controlled PK basis [6].
Reconstitution and handling are practical questions with research-only answers: lyophilized powder, bacteriostatic or sterile water, refrigeration. The identity caveat around TB-500 — fragment versus full-length Thymosin Beta-4 — compounds in unregulated material, where the actual ratio is unverified [4][5]. See the combination research for why that doubled uncertainty matters.
The only human reference points are for the full-length parent
It is worth being precise about what "human dose" data exist, because the blend has none of its own. The human single-agent reference points in the record are for full-length Thymosin Beta-4, not the TB-500 heptapeptide and not the blend: intravenous Thymosin Beta-4 has been reported as well tolerated in early-phase safety work, with dose-proportional pharmacokinetics [4]. BPC-157's human exposure is limited to three small pilot studies — a two-person intravenous safety pilot, an intra-articular knee-pain case series, and a 12-patient intravesical interstitial-cystitis pilot — none of which establishes a dose for the assembled blend [6].
The reviewer's bottom line on dosage is unglamorous and firm. The constituents have animal-model dose records and, for the full-length parent of one of them, a little human safety data. The Wolverine blend has neither a validated dose nor a validated human pharmacokinetic profile, and a fixed-ratio vial is a commercial convention, not a finding [6]. Treat any single number presented as "the dose" with the skepticism a missing study deserves.